Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 29.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Supporters

This activity is supported by educational grants from Celgene Corporation, Eisai Inc., Genentech, and Novartis Pharmaceuticals Corporation.
About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
Physicians’ Education Resource ®, LLC.
All rights reserved.

30th Annual Miami Breast Cancer Conference®

30th Annual Miami Breast Cancer Conference®


Thursday, March 7, 2013 (Mini-Symposium)
12:50 PM Welcome Daniel A. Osman, MD
  Practical Issues for Patients and Physicians  
1:00 PM When Do You Need a PET/CT or MRI in Early Breast Cancer? Elizabeth Morris, MD
1:15 PM The Use of Blood Tests in Breast Cancer for Early Detection and Treatment Emanuel F. Petricoin III, PhD
1:30 PM What Are the Long-Term Side Effects of Chemotherapy and Endocrine Treatment and How to Combat Them Hyman Muss, MD
1:50 PM Management of Early Menopausal Associated Symptoms in Patients with Breast Cancer J. Michael Dixon, MD
2:05 PM Host Factors That Increase Breast Cancer Risk Debu Tripathy, MD
2:20 PM What Patients Can/Cannot Do After Axillary Surgery Anees Chagpar, MD, MSc, MA, MPH
2:35 PM BREAK  
3:20 PM BRCA Gene at Age 20: What Have We Learned? Patrick I. Borgen, MD
3:35 PM The Need for Repeat Biopsy After Recurrence Anees Chagpar, MD, MSc, MA, MPH
3:50 PM How Do You Treat Chemotherapy-Induced Nausea and Vomiting? Hope S. Rugo, MD
4:05 PM ASCO and San Antonio Updates Debu Tripathy, MD
4:20 PM Panel Discussion  
5:20 PM  Adjourn  
6:00 PM Welcome Reception (Exhibit Hall)  
7:00 PM Poster Discussion (General Session Room)  
Friday, March 8, 2013 (Morning Session)
7:50 AM Welcome Daniel A. Osman, MD
8:00 AM Putting Genomics Into Clinical Practice Charles M. Perou, PhD
8:15 AM Use of Genomic Approaches to Select Patients for Targeted Therapy Fabrice André, MD, PhD
8:30 AM Which Translational Research Is Ready for Prime Time? Martine Piccart, MD, PhD
8:45 AM Kinome Profiling: The Potential in ER-Negative Patients Charles M. Perou, PhD
9:00 AM Intratumoral Heterogeneity in the Primary Tumor and Mutational Evolution on Progression Samuel Aparicio, PhD
9:15 AM The Role of Stem Cells in Tumorgenesis- Can We Identify and Inhibit Them? W. Fraser Symmans, MD
  DCIS and Early Breast Cancer  
9:30 AM Are We Overdiagnosing and Overtreating DCIS? Laura Esserman, MD, MBA
9:45 AM Is Gene Expression Profiling the Best Method for Selecting Systemic Therapy? Norman Wolmark, MD
10:00 AM BREAK  
10:45 AM Selecting Individualized Treatment for Patients with DCIS Lawrence J. Solin, MD, FACR, FASTRO
11:00 AM Re-evaluating Axillary Dissection Virgilio Sacchini, MD
11:15 AM Targeting Surgery for Known Axillary Disease Abigail S. Caudle, MD
11:30 AM Should Hypofractionation Be the New Standard After Breast Conserving Surgery? Timothy Whelan, BM, BCh (Oxford), MSc (McMaster), LMCC, DABIM, FRCP(C)
11:45 AM Panel Discussion  
12:45 PM LUNCH  
Friday, March 8, 2013 (Session A) Moderator: J. Michael Dixon, MD
2:00 PM DEBATE: Does Regional Radiation Improve Outcome? Moderator: Patrick I. Borgen, MD
  For Timothy Whelan, BM, BCh (Oxford), MSc (McMaster), LMCC, DABIM, FRCP(C)
  Against J. Michael Dixon, MD
  "How I Do It"  
2:30 PM Skin- and Nipple-Sparing Mastectomy Virgilio Sacchini, MD
2:45 PM Main Factors That Influence Incomplete Excision After Breast-Conserving Surgery J. Michael Dixon, MD
3:00 PM Intraoperative Radiotherapy Mattia Intra, MD
3:15 PM Current Update on the Standard of Care for Accelerated Partial-Breast Radiotherapy-Technique, Efficacy, Toxicities Lawrence J. Solin, MD, FACR, FASTRO
3:30 PM Therapeutic Mammoplasty: Who, How, How Often? Lloyd Gayle, MD
3:45 PM Options in the Management of Central Breast Tumors Mattia Intra, MD
4:00 PM BREAK  
4:45 PM Lipofilling: A New Technique for All Lloyd Gayle, MD
5:00 PM Imaging After Oncoplastic Surgery Elizabeth Morris, MD
5:15 PM Panel Discussion  
5:45 PM Adjourn  
Friday, March 8, 2013 (Session B) Moderator: Debu Tripathy, MD
2:00 PM Is Sentinel Node Biopsy Increasingly Irrevelant in Lieu of Gene Profiling for Prognosis and Prediction? Hyman Muss, MD
2:15 PM Alternate Gene Signatures Charles M. Perou, PhD
2:30 PM Tailoring Adjuvant Hormonal Therapy Lisa Carey, MD
2:45 PM Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar, MD
3:00 PM Adjuvant Therapy for HER2+ Breast Cancer: 1 vs 2 Years Martine Piccart, MD, PhD
3:15 PM Adjuvant Therapy for Older Individuals Hyman Muss, MD
3:30 PM Predicting Survival From Adjuvant Therapy W. Fraser Symmans, MD
3:45 PM Targeting Tumor Vasculature- How to Move Forward? Hope S. Rugo, MD
4:00 PM BREAK  
4:45 PM Circulating Tumor Cells: What Do They Tell Us? Emanuel F. Petricoin III, PhD
5:00 PM Panel Discussion (Difficult Adjuvant Cases) Moderator: Debu Tripathy, MD
5:45 PM Adjourn  
6:15 PM Get Acquainted Reception (Exhibit Hall)  
Saturday, March 9, 2013 (Morning Session) Moderator: Debu Tripathy, MD
8:00 AM Affordable Health Care Act: What It Means for the Physician and the Patient Donna Shalala
8:30 AM The Challenges and the Promises of the Genomic Era George Sledge Jr, MD
8:45 AM Breast Cancer Subgroups and Their Molecular Drivers Samuel Aparicio, PhD
9:00 AM Managing Triple-Negative Tumors in Everyday Practice Lisa Carey, MD
9:15 AM Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, MD
9:30 AM mTOR Inhibitors: Reversing Resistance to Endocrine Blockade Therapy José Baselga, MD, PhD
  Pre-Operative Therapy  
9:45 AM Lessons Learned From Pre-operative Therapy Gunter von Minckwitz, MD, PhD
10:00 AM BREAK  
10:45 AM Predictive Immunohistochemical Biomarkers in the Context of Neoadjuvant Therapy W. Fraser Symmans, MD
11:00 AM Biomarker Implementation: Which Model? Fabrice André, MD, PhD
11:15 AM Neoadjuvant Therapy to Select the Most Effective Drug Combination (I-SPY Trial) Laura Esserman, MD, MBA
11:30 AM Protein Pathway Mapping: Realizing the Promise of Individualized Therapy at the Bedside Emanuel F. Petricoin III, PhD
11:45 AM Assessing Response to Neoadjuvant Therapy Elizabeth Morris, MD
12:00 PM Should Response to Pre-operative Therapy Tailor Radiation, Chemotherapy, Surgical Care? Gunter von Minckwitz, MD, PhD
12:15 PM Panel Discussion  
1:00 PM LUNCH  
Saturday, March 9, 2013 (Session A) Moderator: Patrick I. Borgen, MD
2:15 PM Sentinel Node Biopsy After Pre-operative Therapy Anees Chagpar, MD, MSc, MA, MPH
2:30 PM Management of Uncommon Cancers of the Breast Virgilio Sacchini, MD
2:45 PM Invasive Lobular Carcinoma: Subtypes and Outcomes Mattia Intra, MD
3:00 PM Contralateral Prophylactic Mastectomies: Risks and Benefits Patrick I. Borgen, MD
3:15 PM DEBATE: Are We Doing Too Many Mastectomies?  
  Yes J. Michael Dixon, MD
  No Patrick I. Borgen, MD
3:45 PM Does Everyone With 1-3+ Nodes Need Post-Mastectomy Radiotherapy? Lawrence J. Solin, MD, FACR, FASTRO
4:00 PM What Is New in Breast Reconstruction? Lloyd Gayle, MD
4:15 PM BREAK  
4:45 PM Is There Value to Local Control in Selected Patients with Stage IV Disease? Anees Chagpar, MD, MSc, MA, MPH
5:00 PM Panel Discussion  
6:00 PM Adjourn  
Saturday, March 9, 2013 (Session B) Moderator: Debu Tripathy, MD
2:15 PM My Viewpoint: Can Pathologic Response to Neoadjuvant Therapy Be an FDA- Approvable Endpoint? Laura Esserman, MD, MBA
2:25 PM My Viewpoint: Can Pathologic Response to Neoadjuvant Therapy Be an FDA- Approvable Endpoint? Norman Wolmark, MD
2:35 PM My Viewpoint: Can Pathologic Response to Neoadjuvant Therapy Be an FDA- Approvable Endpoint? Gunter von Minckwitz, MD, PhD
2:45 PM Panel Case  Discussion on Neoadjuvant Therapy  
3:15 PM Front-line Chemotherapy for Advanced Breast Cancer: Is There a Standard? Hope S. Rugo, MD
3:30 PM Chemotherapeutic Choices in Later Lines of Therapy William J. Gradishar, MD
3:45 PM Mutational Evolution in Triple-Negative Breast Cancer Samuel Aparicio, PhD
4:00 PM Progress in Treating Advanced Triple-Negative Breast Cancer Lisa Carey, MD
4:15 PM BREAK  
4:45 PM Advanced HER2+ Breast Cancer: New Options and How to Deploy Them José Baselga, MD, PhD
5:00 PM Combination of Two Anti HER2 Therapies Mark Pegram, MD
5:15 PM Panel Discussion  
6:00 PM Adjourn  
7:00 PM Closing Reception  
Sunday, March 10, 2013 Moderators: J. Michael Dixon, MD
Patrick I. Borgen, MD
8:15 AM Future Direction for NSABP: Clinical Trial Design in an Impatient World Norman Wolmark, MD
8:30 AM Future Prediction for Adjuvant Therapy George Sledge Jr, MD
8:45 AM Predicting Bone Metastasis with Micro RNAs Fabrice André, MD, PhD
9:00 AM Adjuvant Bisphosphonates: Has the Time Come? William J. Gradishar, MD
9:15 AM Update on the New P13K Inhibitors José Baselga, MD, PhD
9:30 AM Strategies to Overcome Resistance to Trastuzumab Mark Pegram, MD
9:45 AM The Role of Epigenetics in Breast Cancer W. Fraser Symmans, MD
10:00 AM Rethinking the Metastatic Cascade as a Therapeutic Target George Sledge Jr, MD
10:15 AM BREAK  
10:45 AM Panel Discussion  
12:00 PM Adjourn  







Become a Member

Forgot Password?
Filter By